Fc gamma receptor (FCGR) I (CD64), FCGR II (CD32) and FCGR III (CD16) comprise three main classes of immunoglobulin G (IgG) binding receptors . Polymorphic FCGR variants were reported to play a role in autoimmune and chronic inflammatory disorders, as well as for the response to certain cancer therapies based on IgG monoclonal antibodies. In metastatic breast cancer the FCGRIIA His133Arg (H131R) polymorphism was reported to affect response to trastuzumab (Herceptin) therapy. Other studies found an association of the FCGRIIIA Phe158Val (F158V) polymorphism and the response to treatment with cetuximab (Erbitux) plus bevacizumab (Avastin) in colorectal cancer.
The FCG StripAssay will cover FCGRIIA H131R and FCGRIIIA F158V.
For more information please visit our webpage www.viennalab.com